Medscape_Oncology_whiteout

Emerging Frontiers in Immunotherapy

Bridging Data and Practice in Solid Tumors CME

Hilton San Diego Bayfront

Saturday, April 18, 2026 | 7:00 pm - 8:30 pm PT

Hybrid

Supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

overview

The solid tumor immunotherapy landscape is evolving rapidly. Join expert faculty for this 90-minute hybrid symposium designed to bridge critical data with clinical practice. This event focuses on novel immunotherapy targets, with an emphasis on melanoma, non-small cell lung cancer (NSCLC), and other solid tumors. Faculty will interpret the latest clinical trial data, discuss the scientific rationale for new targets, and assess actionable strategies for incorporating these advances into modern treatment paradigms.

This symposium is sponsored by Medscape Education and supported by a grant from Regeneron Pharmaceuticals, Inc. This is not an official program of the American Association for Cancer Research Annual Meeting.

faculty

agenda

6:30 PM PT

7:00 PM PT

7:05 PM PT

7:15 PM PT

7:40 PM PT

8:05 PM PT

8:15 PM PT

8:20 PM PT

location

Hilton San Diego Bayfront

1 Park Blvd, San Diego, California, 92101

Indigo Ballroom DH- Level two

target audience

This educational activity is intended for an audience of oncologists, surgeons, dermatologists, nurse practitioners, physician assistants, oncology researchers, and other members of the oncology care team in the United States.

goal statement

The goal of this activity is for learners to be better able to assess the latest immunotherapy clinical data and how it may be applied to future management decisions in solid tumors.

learning objectives

[bold]Upon completion of this activity, participants will be better able to:[/bold] [list][item] Describe rationale for novel immunotherapy targets in solid tumors [item]Interpret the latest clinical trial data for novel immunotherapies in solid tumors [item]Identify applications of novel immunotherapies across solid tumors, as clinically available [item]Assess emerging strategies for incorporating novel immunotherapies into solid tumor treatment paradigms [item]Describe the rationale for novel immunotherapy targets in solid tumors [/list]

accreditation statement

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

accreditation logo
medscape logo
[title]For Physicians[/title] [text]Medscape, LLC designates this live activity for a maximum of 1.50 [bold][italic]AMA PRA Category 1 Credit(s)[/italic][super]TM[/super][/bold]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.[/text]